About

A running record of every orexin receptor agonist in clinical development. It exists because the information is scattered across sponsor press releases, trial registry entries, earnings calls and regulatory announcements, and because most secondary coverage of this class is either out of date or wrong about which phase a compound is in.

The core of it is narrow: what each compound is, who owns it, how far it has come, what it is aimed at, and where that claim came from. Alongside that, a research section covers the peer-reviewed literature on the orexin system, and program pages list the papers reporting human data on that specific compound.

Where a paper is cited, this site reports what was published and links to it. It does not reproduce abstracts, figures or tables, and it does not restate a number in a way that could be read as advice about a dose or a treatment. A result reported in a trial is a fact about that trial. Turning it into a recommendation is a doctor's job, and it is done with a patient in the room.

Simon Stawski. I am not a doctor, a pharmacologist, or an employee of any company in this field, and this site carries no clinical authority. What it has is a method. Every claim is checked against a primary source, dated, and linked, so you can verify any of it without taking my word for it.

I follow health and biotech as an outsider. Orexin kept coming up. When I went looking for a plain answer about how far along it actually was, what I found was out of date or disagreed with the registry. So I built the record I wanted to read.

Corrections go to corrections@getorexin.com and are logged with a date. My other writing is at simonstawski.com.

Every entry is checked against a primary source: the sponsor's own announcement or pipeline page, a ClinicalTrials.gov registry record, a regulatory announcement, or a peer-reviewed publication. Secondary coverage is not treated as a source, only as a pointer to one.

Each program carries its own verified date rather than a site-wide one, so a reader can see exactly how current any single claim is. Where an entry cannot be confirmed against a live primary source, it is marked as needing re-checking on the page itself rather than quietly left in place.

Claims are kept as close to the source as the language allows. Where a registry label is misleading — TAK-360's extension study carries a Phase 2/3 label without being a pivotal trial — the discrepancy is stated rather than smoothed over.

Send corrections to corrections@getorexin.com with a primary source. Substantive corrections are made and logged in the changelog with the date, rather than edited in silently.

A tracker's only asset is being right. If something here is wrong, that is worth more to this site than it is to you.

This site is not affiliated with, funded by, or reviewed by any pharmaceutical company, and it sells nothing. There are no affiliate links and no sponsored entries. Compounds are listed on the basis of being in clinical development, and nothing else.

Email alerts are free. The subscriber list is not for sale or rent, and messages carry no tracking pixels.

This site reports on drug development. It does not give medical advice and is not a substitute for a doctor. Decisions about treatment belong with a qualified clinician who knows the patient.

There are exactly two lawful routes to any drug in this class: a prescription in a country where it is approved, or enrolment in a clinical trial. Anything sold online under an orexin-adjacent name is neither.